Patient characteristics and clinical outcome
| UPN . | Age/Sex . | Clinical Stage . | Histology/Grade . | Prior Chemotherapy/Response* . | Time to vaccination (months)** . | Prevaccine Status . | Postvaccine Status (months)*** . |
|---|---|---|---|---|---|---|---|
| 1 | 32/M | IVA | FL/2 | PACE/PR | 9 | PR | SD (22)# |
| 2 | 56/F | IVA | FL/2 | PACE/PR | 10 | PR | PD (15) |
| 3 | 33/M | IVA | FL/1 | PACE/PR | 8 | PR | PD (17) |
| 4 | 42/M | IVA | FL/1 | PACE/CR | 83 | PD## | PD (10) |
| 5 | 53/M | IVA | FL/1 | PACE/CR | 20 | PD## | CR (30+)### |
| 6 | 53/F | IVA | FL/1 | PACE/CR | 12 | PD## | PD (12) |
| 7 | 20/F | IVA | FL/1 | PACE/PR | 8 | PD## | PD (3) |
| 8 | 60/M | IVA | FL/1 | PACE/CR | 15 | PD## | PD (8) |
| 9 | 48/M | IIIA | FL/2 | None | n/a | PD## | PD (5) |
| 10 | 44/M | IIIA | FL/1 | None | n/a | PD## | PD (3) |
| 11 | 52/M | IVA | FL/2 | None | n/a | PD## | PD (2) |
| UPN . | Age/Sex . | Clinical Stage . | Histology/Grade . | Prior Chemotherapy/Response* . | Time to vaccination (months)** . | Prevaccine Status . | Postvaccine Status (months)*** . |
|---|---|---|---|---|---|---|---|
| 1 | 32/M | IVA | FL/2 | PACE/PR | 9 | PR | SD (22)# |
| 2 | 56/F | IVA | FL/2 | PACE/PR | 10 | PR | PD (15) |
| 3 | 33/M | IVA | FL/1 | PACE/PR | 8 | PR | PD (17) |
| 4 | 42/M | IVA | FL/1 | PACE/CR | 83 | PD## | PD (10) |
| 5 | 53/M | IVA | FL/1 | PACE/CR | 20 | PD## | CR (30+)### |
| 6 | 53/F | IVA | FL/1 | PACE/CR | 12 | PD## | PD (12) |
| 7 | 20/F | IVA | FL/1 | PACE/PR | 8 | PD## | PD (3) |
| 8 | 60/M | IVA | FL/1 | PACE/CR | 15 | PD## | PD (8) |
| 9 | 48/M | IIIA | FL/2 | None | n/a | PD## | PD (5) |
| 10 | 44/M | IIIA | FL/1 | None | n/a | PD## | PD (3) |
| 11 | 52/M | IVA | FL/2 | None | n/a | PD## | PD (2) |
UPN indicates unique patient number; FL, follicular lymphoma; PACE, prednisone, doxorubicin, cyclophosphamide, and etoposide; PR, partial response; SD, stable disease; PD, progressive disease; CR, complete response.
Best response to chemotherapy
Time to vaccination from last chemotherapy
Months after starting vaccination.
Lost to follow-up
The duration of progressive disease varied from 6 to 12 months prior to vaccine administration
Remains in complete remission 44 months after completion of the vaccination.